Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REMORA: Phase II trial of lenvatinib in metastatic or recurrent thymic carcinoma
jRCT2091220285Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in thymic carcinoma (TC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Response rate (central review). Started Apr 2017; status: completed.
02
Drugs
lenvatinib
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on jRCT2091220285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2091220285.